ADXN

Addex Therapeutics Ltd NASDAQ Listed Feb 12, 2020

Healthcare ·Biotechnology ·CH · addextherapeutics.com

$7.01

Mkt Cap $4.6M

52w Low $5.41 24.1% of range 52w High $12.05

50d MA $6.73 200d MA $7.95

P/E (TTM) 0.8x

EV/EBITDA -0.4x

P/B 0.6x

Debt/Equity 0.0x

ROE —

P/FCF -1.0x

RSI (14) —

ATR (14) —

Beta 1.86

50d MA $6.73

200d MA $7.95

Avg Volume 4.3K

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

SIC Code

2834

CIK (SEC)

1574232

Phone

41 22 884 1555

Chemin des Mines, 9 · Geneva, V8 1202 · CH

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Dec 4, 2025	AMC	—	-1.50	—	8.38	-8.7%	-7.3%	+3.6%	-5.7%	+0.0%	+6.7%	—
Jun 20, 2025	AMC	-4.26	-1.33	+68.8%	8.46	-3.3%	-3.0%	+7.7%	+3.6%	-3.8%	+2.2%	—
Apr 7, 2025	AMC	-1.42	-1.63	-14.7%	7.16	-2.9%	-9.1%	+0.0%	+5.5%	+6.1%	-4.4%	—
Nov 22, 2024	AMC	-1.40	-2.77	-97.9%	7.53	+1.5%	+5.6%	+10.4%	-1.8%	+1.0%	-4.0%	—
Sep 30, 2024	AMC	-0.01	-1.77	-9999.0%	9.77	-0.2%	-5.5%	+0.5%	+1.3%	+0.4%	-1.1%	—
Jun 6, 2024	AMC	-0.44	-1.37	-210.3%	9.20	-3.3%	-2.2%	+1.3%	-3.0%	-4.0%	+1.8%	—
Apr 18, 2024	AMC	-0.66	-4.06	-513.0%	20.96	-1.7%	-4.3%	-3.8%	-2.8%	-17.0%	-0.9%	—
Nov 29, 2023	AMC	-4.00	-4.07	-1.8%	5.71	-3.3%	-2.8%	+4.1%	+5.5%	-4.9%	-5.2%	—
Aug 10, 2023	AMC	-0.83	-5.00	-506.0%	11.20	-1.8%	+1.1%	-5.5%	-0.4%	-0.2%	-1.1%	—
May 11, 2023	AMC	-1.03	-5.20	-404.2%	17.78	-1.1%	-1.0%	-4.2%	-10.4%	+4.6%	-4.9%	—
Mar 9, 2023	AMC	-0.31	-0.83	-167.7%	28.60	-2.8%	-11.9%	-15.9%	+22.6%	-15.4%	+10.5%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Jul 31	HC Wainwright & Co.	Upgrade	Neutral → Buy	—	$8.00	$8.35	+4.4%	+2.0%	-2.0%	-1.2%	-8.9%	+9.3%
Jun 22	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$25.10	$25.20	+0.4%	-11.8%	+3.0%	-3.5%	+2.6%	-7.0%
May 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—
Feb 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$110.40	$116.20	+5.3%	+3.8%	-2.6%	-8.4%	+11.4%	-1.7%

Data updated apr 26, 2026 9:27am · Source: massive.com